The Clinical Significance of Plasma Pentraxin 3 levels for Patients with Diastolic Heart Failure

The Clinical Significance of Plasma Pentraxin 3 levels for Patients with Diastolic Heart Failure - Pentaraxin 3 in Left Ventricular Diastolic Dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002170

Enrollment

200

Registered

2009-07-08

Start date

2006-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with heart failure who are admitted to our hospital are enrolled. The diagnosis of heart failure is based on guidelines. This study also enrolles control subjects in our hospital during the same enrollment period.

Exclusion criteria

Exclusion criteria: Exclusion criteria include active systemic inflammatory diseases, chronic renal failure requiring hemodialysis, active hepatic diseases, collagen diseases, presence of malignant tumor or acute coronary syndrome within 3 months preceding admission.

Design outcomes

Primary

Measure	Time frame
The clinical significance of plasma PTX3 levels for patients with left ventricular diastolic dysfunction	—

Secondary

Measure	Time frame
cardiovascular events, which were a composite of CV death, non-fatal myocardial infarction or ischemic stroke, unstable angina, hospitalization for HF, or coronary revascularization.	—

Countries

Japan

Contacts

Public ContactJunichi Matsubara

Faculty of Life Sciences, Kumamoto University Department of Cardiovascular Medicine

j-matsu@kumamoto-u.ac.jp096-373-5175

Outcome results